India, March 5 -- Aurobindo Pharma said that its wholly owned step down subsidiary Auro Vaccines has terminated its License Agreement with Hilleman Laboratories Singapore Pte. Limited, effective March 5, 2025.
The agreement, originally signed on September 27, 2023, was focused on the development, manufacturing, and commercialization of a pentavalent vaccine candidate for children's immunization.
Auro Vaccines is not considered a material subsidiary, and the termination of this early-stage vaccine asset agreement is not deemed a material event. The Company has stated that this decision will not have any significant financial or operational impact on itself or its subsidiaries. Any future material developments will be duly disclosed to the...